Publication: The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: a milder course?
dc.contributor.coauthor | Şen, S. | |
dc.contributor.coauthor | Tuncer, A. | |
dc.contributor.coauthor | Özakbaş, S. | |
dc.contributor.coauthor | Uzunköprü, C. | |
dc.contributor.coauthor | Baba, C. | |
dc.contributor.coauthor | Demir, S. | |
dc.contributor.coauthor | Beckmann, Y. | |
dc.contributor.coauthor | Gümüş, H. | |
dc.contributor.coauthor | Arslan, G. | |
dc.contributor.coauthor | Kılıç, A.K. | |
dc.contributor.coauthor | Yüceyar, N. | |
dc.contributor.coauthor | Turan, O.F. | |
dc.contributor.coauthor | Tütüncü, M. | |
dc.contributor.coauthor | Terzi, M. | |
dc.contributor.coauthor | Acar, P. | |
dc.contributor.coauthor | Bünül, S.D. | |
dc.contributor.coauthor | Balcı, B.P. | |
dc.contributor.coauthor | Bir, L.S. | |
dc.contributor.coauthor | Köseoğlu, M. | |
dc.contributor.coauthor | Mungan, S. | |
dc.contributor.coauthor | Gündüz, T. | |
dc.contributor.coauthor | Doğan, I.G. | |
dc.contributor.coauthor | Kotan, D. | |
dc.contributor.coauthor | Uygunoğlu, U. | |
dc.contributor.coauthor | Ekmekçi, O. | |
dc.contributor.coauthor | Demirkiran, M. | |
dc.contributor.coauthor | Kamışlı O. | |
dc.contributor.coauthor | Kabay, S.C. | |
dc.contributor.coauthor | Tamam, Y. | |
dc.contributor.coauthor | Ömerhoca, S. | |
dc.contributor.coauthor | Sevim, S. | |
dc.contributor.coauthor | Güler, S. | |
dc.contributor.coauthor | Kürtüncü, M. | |
dc.contributor.coauthor | Efendi, H. | |
dc.contributor.coauthor | Karabudak, R. | |
dc.contributor.coauthor | Şiva A. | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Altıntaş, Ayşe | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T13:23:29Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective methods: the aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: the study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: in NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.version | Publisher version | |
dc.description.volume | 58 | |
dc.identifier.doi | 10.1016/j.msard.2021.103399 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR03468 | |
dc.identifier.issn | 2211-0348 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85122957692 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/3372 | |
dc.identifier.wos | 793561600010 | |
dc.keywords | Coronavirus | |
dc.keywords | Disease modifying treatment | |
dc.keywords | Myelin oligodendrocyte glycoprotein antibody-associated disorders | |
dc.keywords | Neuromyelitis optica spectrum disorders | |
dc.keywords | SARS-CoV-2 | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.grantno | NA | |
dc.relation.ispartof | Multiple Sclerosis and Related Disorders | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10262 | |
dc.subject | Medicine, general and internal | |
dc.title | The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: a milder course? | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Altıntaş, Ayşe | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
Files
Original bundle
1 - 1 of 1